Centenial Surgical Suture
- Market cap
- ₹ 25 Cr.
- P/E
- 52.5x
- P/B
- 0.91x
- 52-week range
- 66.6 – 124.9
- ROE
- −7%
- ROCE
- 2.5%
- Dividend yield
- 0%
- Debt / equity
- 1.04
- Sector
- Healthcare Equipment & Supplies
- Industry
- Medical Equipment & Supplies
- Listed on
- BSE
About
Centenial Surgical Suture Limited is an India-based company, which is engaged in the development, manufacturing and supply of medical devices. The Company operates through the Medical Devices segment. The Company's products include absorbable sutures, non-absorbable sutures, superior atraumatic needles, cardiovascular sutures, and other medical devices. Its absorbable sutures consist of catgut, centicryl, centicryl rapid, centisorb, centisorb rapid, centisorb tri-plus +, centisynth, and monosynth. Its non-absorbable sutures consist of centibond, centidene, centilene, centisilk, centlon, and centsteel. Its superior atraumatic needles consist of centibond, centiiwax, centilene, and centsteel. Its other medical devices include centipunch, centcel, centiitape, centiiwax, centipace, centipled, and disposable skin stapler close.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Medical Equipment & Supplies: 25 companies →Centenial Surgical Suture against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)52.5 against a typical 28.7: pricier than most peers (1st = cheapest).20th of 25
- Sales growth+18.5% against a typical +21.5% from a year earlier.12th of 18
- Share price, 3 months−15.2% against a typical −7.9%.15th of 23
- Size₹ 24.8 Cr. market value against a typical ₹ 238.1 Cr. (1st = largest).23rd of 24
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13 | 12 | 12 | 14 | 14 | 12 | 13 | 13 | 13 | 15 | 13 | 15 |
| Expenses | 12 | 11 | 11 | 12 | 13 | 11 | 11 | 12 | 12 | 13 | 12 | 13 |
| Operating Profit | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 2 | 1 | 2 |
| OPM % | 8.7% | 9.6% | 12.5% | 12.5% | 12.1% | 6.2% | 15.5% | 9.5% | 10.3% | 10.3% | 7.4% | 14.2% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 2 | 0 |
| Depreciation | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | −1 | −1 | −0 | −0 | 0 | −2 | 1 |
| Tax % | 28.1% | 24.4% | −26.7% | 25% | 23.5% | 0% | −11.2% | 0% | 0% | 26.3% | 4% | 25.5% |
| Net Profit | 0 | 0 | 0 | 0 | 0 | −1 | −1 | −0 | −0 | 0 | −2 | 1 |
| EPS in Rs | 0.66 | 0.85 | 0.52 | 0.82 | 0.36 | −2.33 | −3.23 | −0.11 | −0.03 | 0.41 | −6.33 | 2.03 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 0%
- 5 Years
- 8%
- 3 Years
- 1%
- TTM
- 7%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 26%
- 10 Years
- 2%
- 5 Years
- 13%
- 3 Years
- 5%
- TTM
- —
- 10 Years
- 2%
- 5 Years
- −1%
- 3 Years
- −3%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Centenial Surgical Suture | ₹ 71.25 | ₹ 25 Cr. | 52.5x | 0.9x | −7% | — |
| Lenskart Solutions | ₹ 627.55 | ₹ 1,08,959 Cr. | 181x | 10.7x | 6.7% | 5.7% |
| Poly Medicure | ₹ 1,446.80 | ₹ 14,582 Cr. | 52.1x | 5.5x | 11% | 17.1% |
| Laxmi Dental | ₹ 171.25 | ₹ 946 Cr. | 35.6x | 5x | 12.8% | 9.5% |
| One Global Service Provider | ₹ 372.00 | ₹ 721 Cr. | 17x | 8.3x | 65.2% | 14% |
| Mallcom (India) | ₹ 909.00 | ₹ 567 Cr. | 21.9x | 2.1x | 9.7% | 5.6% |
Management
- Vijay Majrekar
- Chairman of the Board, Chief Executive Officer, Managing Director
- Anuradha Kashikar
- Chief Financial Officer, Executive Director
- J. Rathod
- Chief Operating Officer
- S. Mhatre
- Chief Administrative Officer
- Mahima Bathwal
- Compliance Officer, Company Secretary
- Devraj T. Poojary
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.